Prof Garry Taylor:
Professor of Molecular Biophysics

Prof Garry Taylor

Prof Garry Taylor
Biomolecular Sciences Building
University of St Andrews
North Haugh
St Andrews
KY16 9ST

tel: 01334 467301
fax: 01334 462595
room: B203

Related Content:

Taylor Group

Structural Biology
School of Biology
Molecular and Structural Virology
Structural Biology of Infection & Immunity
Biomedical Sciences Research Complex

edit glt2 details

We are using molecular, cellular and structural biology to understand the structure and function of proteins involved in pathogenesis with a view to developing new drugs against a range of disease caused by microorganisms. The sialidase (or neuraminidase) superfamily are virulence factors in influenza, parainfluenza, cholera and pneumonia. Our structural studies on the paramyxovirus hemagglutinin-neuraminidase (HN) has led to the structure-based development of a new drug that is a potential treatment for childhood parainfleunza. We are currently studying the sialidases from Streptococcus pneumoniae and Pseudomonas aeruginosa, and developing inhibitors against these enzymes that are key virulence facotrs in the respiratory diseases caused by these bacteria.

More recently, we have engineered mutlivalent forms of a couple of carbohydrate-binding modules specific for sialic acid, a key component of the receptor used by the influenza virus, parainfluenza virus, some coronaviruses and pneumococci. Experients in mice using lethal viral challenges show that these mutlivalent bioloigcs have great potential as a prophylactic for the prevention of certain respiratory diseases.


source: symbiosis

Recent Publications:

Recent publications listed in research@st-andrews
Owen, CD, Tailford, LE, Monaco, S, Šuligoj, T, Vaux, L, Lallement, R, Khedri, Z, Yu, H, Lecointe, K, Walshaw, J, Tribolo, S, Horrex, M, Bell, A, Chen, X, Taylor, GL, Varki, A, Angulo, J & Juge, N 2017, 'Unravelling the specificity and mechanism of sialic acid recognition by the gut symbiont Ruminococcus gnavus' Nature Communications, vol 8, 2196. DOI: 10.1038/s41467-017-02109-8
Lu, T, Zou, Y, Xu, G, Potter, JA, Taylor, GL, Duan, Q, Yang, Q, Xiong, H, Qiu, H, Ye, D, Zhang, P, Yu, S, Yuan, X, Zhu, F, Wang, Y & Xiong, H 2016, 'PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK' Oncotarget, vol 7, no. 50, pp. 83017-83030. DOI: 10.18632/oncotarget.12940
Taylor, GL & Connaris, H 2015, Immunomodulatory Compounds, Patent No. WO2015110831 (A1) , IPC No. A61K31/74.